Bio-Works secures another order from PolyPeptide

Press release October 23, 2018

Bio-Works has received an order of 1,6 million SEK from PolyPeptide. In total, Bio-Works has received seven orders from PolyPeptide, four during 2017 and three during 2018. PolyPeptide is one of the largest contract manufacturers in the world for peptide pharmaceuticals. They control 25 % of the global market for contract manufacturing of peptide pharmaceuticals. This latest order will be delivered during the first quarter of 2019.

Mats Johnson, Bio-Works CEO:

”We are happy that PolyPeptide uses Bio-Works’ products for optimal production efficiency. The high frequency of orders from PolyPeptide shows the trust they have for our products. We look forward to a continued good collaboration.”

Bio-Works has seen a clear increase in recurring orders from both existing and new customers. The order values are also increasing and the customer base is growing. Of the 203 customers Bio-Works has presently, 45 projects are in scale-up and four in production phase. We expect that several of our customers’ scale-up projects will move into production in the coming months. In industrial production each project a customer is running can be worth up to 10 million SEK in yearly revenue for Bio-Works.

For more information please visit Bio-Works’ homepage,,com, or contact Mats Johnson, CEO for Bio-Works, e-mail:, telephone: +46 70 516 53 37.

About Bio-Works

Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media. Bio-Works’ agarose-based high performance products are used for purification in the life science research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally through our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follow the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.